Press releases
- Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints
- Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC)as Monotherapy for Advanced Gastric Cancer
- Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO)
- Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
- Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)
- Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
- Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
- Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
- Innovent Announces 2023 Annual Results and Business Updates
- Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
More ▼
Key statistics
On Friday, Innovent Biologics Inc (6IB:DUS) closed at 4.68, -16.43% below its 52-week high of 5.60, set on Nov 07, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.62 |
---|---|
High | 4.68 |
Low | 4.62 |
Bid | 4.70 |
Offer | 4.82 |
Previous close | 4.56 |
Average volume | 0.00 |
---|---|
Shares outstanding | 1.63bn |
Free float | 1.51bn |
P/E (TTM) | -- |
Market cap | 65.17bn HKD |
EPS (TTM) | -0.7044 HKD |
Data delayed at least 15 minutes, as of May 17 2024 18:30 BST.
More ▼